TY - JOUR A1 - Tacke, Reinhold A1 - Wiesenberger, Frank T1 - (Acetoxymethyl)methylphenylgerman: Synthese, thermisches Verhalten und olfaktorische Eigenschaften T1 - (Acetoxymethyl)methylphenylgermane: Synthesis, Thermal Behaviour and Olfactoric Properties N2 - No abstract available. KW - Chemische Synthese KW - Temperaturabhängigkeit KW - Olfaktorische Analyse KW - (Acetoxymethyl)methylphenylgermane KW - (Acetoxymethyl)methylphenylsilane KW - hydratropyl acetate KW - thermal stability KW - perfumes Y1 - 1991 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-86927 ER - TY - JOUR A1 - Tacke, Reinhold A1 - Sperlich, Jörg A1 - Strohmann, Carsten A1 - Frank, Brigitta A1 - Mattern, Günter T1 - Bis[3,4,5,6-tetrabrom-1,2-benzoldiolato(2-)]-(pyrrolidiniomethyl)silicat-Acetonitril-Solvat [(C6Br4O2)2SiCH2(H)NC4H8 · CH3CN]: Synthese sowie Kristall- und Molekülstruktur eines zwitterionischen [lambda]5-Spirosilicats N2 - Single crystal X-ray studies on bis[3,4,5,6-tetrabromo-1 ,2-benzenediolato(2- )](pyrrolidiniomethyl)silicate acetonitrile solvate [(C6Br40 2hSiCH2(H)NC4H8 · CH3CN; monoclinic, P2t/c, a = 808.5(4), b = 1533.0(8), c = 2212.6(1) pm, ß = 97.67(2)0 , Z = 4] revealed a zwitterionic structure with a pentacoordinate, formally negatively charged silicon atom and a positively charged ammonium moiety. The silicon atom is surrounded by four oxygen atoms and one carbon atom in a trigonalbipyramidal fashion, with the carbon atom in an equatorial position. The structure is displaced by 7.0% from the trigonal bipyramid towards the square pyramid. The zwitterion and the CH3CN molecule form intermolecular N-H · · · N hydrogen bonds. KW - Kristallstruktur KW - Spirosilicate KW - crystal structure KW - zwitterionic spirosilicate Y1 - 1992 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-86884 ER - TY - JOUR A1 - Tacke, Reinhold A1 - Wiesenberger, Frank A1 - Lopez-Mras, Angel A1 - Sperlich, Jörg A1 - Mattern, Günter T1 - Neuartige zwitterionische λ5-Spirosilicate: Synthese und Kristallstruktur von Bis[1,2-benzoldiolato(2-)][2-(dimethylammonio)phenyl]silicat sowie Synthese von Bis[2,3-naphthalindiolato(2-)][2-(dimethylammonio)phenyl]silicat-Hemiacetonitril-Solvat N2 - No abstract available. KW - Silicate KW - Bis[1,2-benzenediolato(2-)][2-(dimethylammonio)phenyl]silicate KW - Bis[2,3-naphthalenediolato(2-)][2-(dimethylammonio)phenyl]silicate KW - zwitterionic λ5-Spirosilicates Y1 - 1992 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-86916 ER - TY - JOUR A1 - Tacke, Reinhold A1 - Kropfgans, Martin A1 - Tafel, Andrea A1 - Wiesenberger, Frank A1 - Sheldrick, William S. A1 - Mutschler, Ernst A1 - Egerer, Hansjörg A1 - Rettenmayr, Nikola A1 - Gross, Jan A1 - Waelbroeck, Magali A1 - Lambrecht, Günter T1 - (Hydroxymethyl)diphenyl(piperidinoalkyl)silane des Typs (HOCH2)(C6H5)2Si(CH2)nNC5H10 (n = 2,3) und deren Methoiodide: Synthese, Struktur und antimuscarinische Eigenschaften N2 - No abstract available. KW - (Hydroxymethyl)diphenyl(piperidinoalkyl)silanes KW - Sila-pridinol KW - Sila-difenidol KW - muscarinic antagonists KW - muscarinic receptors Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-86904 ER - TY - JOUR A1 - Wilde, Anne-Christin Beatrice A1 - Lieb, Charlotte A1 - Leicht, Elise A1 - Greverath, Lena Maria A1 - Steinhagen, Lara Marleen A1 - Wald de Chamorro, Nina A1 - Petersen, Jörg A1 - Hofmann, Wolf Peter A1 - Hinrichsen, Holger A1 - Heyne, Renate A1 - Berg, Thomas A1 - Naumann, Uwe A1 - Schwenzer, Jeannette A1 - Vermehren, Johannes A1 - Geier, Andreas A1 - Tacke, Frank A1 - Müller, Tobias T1 - Real-world clinical management of patients with primary biliary cholangitis — a retrospective multicenter study from Germany JF - Journal of Clinical Medicine N2 - Background: Clinical practice guidelines for patients with primary biliary cholangitis (PBC) have been recently revised and implemented for well-established response criteria to standard first-line ursodeoxycholic acid (UDCA) therapy at 12 months after treatment initiation for the early identification of high-risk patients with inadequate treatment responses who may require treatment modification. However, there are only very limited data concerning the real-world clinical management of patients with PBC in Germany. Objective: The aim of this retrospective multicenter study was to evaluate response rates to standard first-line UDCA therapy and subsequent Second-line treatment regimens in a large cohort of well-characterized patients with PBC from 10 independent hepatological referral centers in Germany prior to the introduction of obeticholic acid as a licensed second-line treatment option. Methods: Diagnostic confirmation of PBC, standard first-line UDCA treatment regimens and response rates at 12 months according to Paris-I, Paris-II, and Barcelona criteria, the follow-up cut-off alkaline phosphatase (ALP) ≤ 1.67 × upper limit of normal (ULN) and the normalization of bilirubin (bilirubin ≤ 1 × ULN) were retrospectively examined between June 1986 and March 2017. The management and hitherto applied second-line treatment regimens in patients with an inadequate response to UDCA and subsequent response rates at 12 months were also evaluated. Results: Overall, 480 PBC patients were included in this study. The median UDCA dosage was 13.2 mg UDCA/kg bodyweight (BW)/d. Adequate UDCA treatment response rates according to Paris-I, Paris-II, and Barcelona criteria were observed in 91, 71.3, and 61.3% of patients, respectively. In 83.8% of patients, ALP ≤ 1.67 × ULN were achieved. A total of 116 patients (24.2%) showed an inadequate response to UDCA according to at least one criterion. The diverse second-line treatment regimens applied led to significantly higher response rates according to Paris-II (35 vs. 60%, p = 0.005), Barcelona (13 vs. 34%, p = 0.0005), ALP ≤ 1.67 × ULN and bilirubin ≤ 1 × ULN (52.1 vs. 75%, p = 0.002). The addition of bezafibrates appeared to induce the strongest beneficial effect in this cohort (Paris II: 24 vs. 74%, p = 0.004; Barcelona: 50 vs. 84%, p = 0.046; ALP < 1.67 × ULN and bilirubin ≤ 1 × ULN: 33 vs. 86%, p = 0.001). Conclusion: Our large retrospective multicenter study confirms high response rates following UDCA first-line standard treatment in patients with PBC and highlights the need for close monitoring and early treatment modification in high-risk patients with an insufficient response to UDCA since early treatment modification significantly increases subsequent response rates of these patients. KW - primary biliary cholangitis KW - autoantibodies KW - ursodeoxycholic acid KW - treatment response KW - second line therapy Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234003 SN - 2077-0383 VL - 10 IS - 5 ER -